Fig. 4

Bisphosphonate use according to renal function at initiation of 1 L treatment The proportion of patients who received treatment with bisphosphonates according to RI severity at initiation of 1 L treatment. Mild RI: CrCl ≥50 mL/min; moderate RI: CrCl 30–49 mL/min; severe RI: CrCl < 30 mL/min. Data are presented for the aggregated analysis across the EU5. Aggregated EU5 data have been weighted based on the multiple myeloma incidence in each country so base sizes for individual countries may not equal the EU5 total. CrCl creatinine clearance, EU5 five European countries (France, Germany, Italy, Spain and the United Kingdom), 1 L first line, RI renal impairment